Tag Archive for: ionctura

iOnctura reaches new clinical milestones in uveal melanoma

Completed Phase I DIONE-01 study demonstrates clinical activity and long-term safety of roginolisib, a unique allosteric modulator of PI3Kδ Patients with uveal melanoma showed a doubling of overall survival compared to historical controls Site activation ongoing for randomized Phase II OCULE-01 study in uveal melanoma Geneva, Switzerland and Amsterdam, The Netherlands, 11 Dec 2024 – […]

Weekly round-up: Optimum’s clients show their expertise, as excitement builds ahead of Scrip Awards

It’s been a busy week for Optimum, with some amazing original content from our clients, with this week’s podcast highlighting their expertise in cutting-edge lung cancer research. In our weekly hot topic article, they give predictions for the 2025 outlook following November’s London Life Sciences Week. We also have five clients nominated for the prestigious […]

iOnctura announces expansion of roginolisib clinical trial program to NSCLC

• Phase II study in non-small-cell-lung-cancer (NSCLC) to be run in collaboration with the ETOP IBCSG Partners Foundation across sites in Europe • Study will investigate dostarlimab + roginolisib +/- docetaxel in patients with NSCLC resistant to first-line checkpoint inhibitor therapy Geneva, Switzerland and Amsterdam, The Netherlands, 9 July 2024 – iOnctura, a clinical-stage biopharmaceutical […]

iOnctura announces EUR80 million Series B financing to progress pipeline through Phase II trials

• Led by new investor Syncona, with participation from the European Innovation Council Fund as well as existing investors • To progress pipeline of innovative, first-in-class, oral cancer treatments targeting neglected and hard-to-treat cancers • To accelerate development of lead asset roginolisib for treatment of uveal melanoma and a number of other oncology indications Geneva, […]

Optimum’s clients build momentum in March

Optimum’s clients continued to gain momentum in March, starting things off on Monday with a substantial financing agreement for Heidelberg Pharma, with HealthCare Royalty for up to $115 million. On Wednesday, Heidelberg followed this with the announcement that it is to present first efficacy data from a Phase 1 clinical trial with ATAC candidate HDP-101. […]